Drug firm Orchid Pharma today said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in Tamil Nadu.
The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to BSE.
"The facility was inspected by the USFDA in December 2016," it added.
Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings.
Shares of Orchid Pharma today closed at Rs 36.55 per scrip on BSE, up 5.33 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
